These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36328326)

  • 21. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada.
    Iskedjian M; Walker JH; Hemels ME
    Vaccine; 2004 Oct; 22(31-32):4215-27. PubMed ID: 15474711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ADVERSE EVENTS POST-DTAP AND DTwP VACCINATION IN THAI CHILDREN.
    Fortuna L; Sirivichayakul C; Watanaveeradej V; Soonthornworasiri N; Sitcharungsi R
    Southeast Asian J Trop Med Public Health; 2015 Jul; 46(4):764-74. PubMed ID: 26867397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Whole-Cell or Acellular Pertussis Primary Immunizations in Infancy Determines Adolescent Cellular Immune Profiles.
    van der Lee S; Hendrikx LH; Sanders EAM; Berbers GAM; Buisman AM
    Front Immunol; 2018; 9():51. PubMed ID: 29416544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
    Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
    Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between pertussis vaccination coverage and other sociodemographic factors and pertussis incidence using surveillance data.
    Rane MS; Wakefield J; Rohani P; Halloran ME
    Epidemics; 2023 Sep; 44():100689. PubMed ID: 37295130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany.
    Tormans G; Van Doorslaer E; van Damme P; Clara R; Schmitt HJ
    Eur J Pediatr; 1998 May; 157(5):395-401. PubMed ID: 9625337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of universal adult immunization with tetanus-diphtheria-acellular pertussis vaccine (Tdap) versus current practice in Brazil.
    Fernandes EG; Sartori AMC; de Soárez PC; Amaku M; de Azevedo Neto RS; Novaes HMD
    Vaccine; 2020 Jan; 38(1):46-53. PubMed ID: 31648911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of a pertussis vaccination programme for Japan considering intergenerational infection.
    Itatani T; Shimizu S; Iwasa M; Ohkusa Y; Hayakawa K
    Vaccine; 2013 Jun; 31(27):2891-7. PubMed ID: 23570987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis.
    Terranella A; Asay GR; Messonnier ML; Clark TA; Liang JL
    Pediatrics; 2013 Jun; 131(6):e1748-56. PubMed ID: 23713104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An economic evaluation of universal pertussis vaccination in Italy.
    Beutels P; Bonanni P; Tormans G; Canale F; Crovari PC
    Vaccine; 1999 May; 17(19):2400-9. PubMed ID: 10392622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccine in Adults in Japan.
    Ujiie M; Tsuzuki S; Suzuki M; Ota M; Suzuki T; Nomoto H; Yamamoto K; Saito S; Kokaze A; Kinoshita N
    Jpn J Infect Dis; 2021 Sep; 74(5):399-404. PubMed ID: 33518629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimating Population-Level Effects of the Acellular Pertussis Vaccine Using Routinely Collected Immunization Data.
    Rane MS; Halloran ME
    Clin Infect Dis; 2021 Dec; 73(11):2101-2107. PubMed ID: 33881527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duration of Immunity and Effectiveness of Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children.
    Domenech de Cellès M; Rohani P; King AA
    JAMA Pediatr; 2019 Jun; 173(6):588-594. PubMed ID: 31009031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of acellular pertussis-tetanus-diphtheria vaccines and whole-cell pertussis-tetanus-diphtheria vaccines in infancy.
    Korkmaz HA; Aydin A; Unal B
    Paediatr Int Child Health; 2014 Aug; 34(3):198-202. PubMed ID: 24621240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of models to identify cost-effective interventions: pertussis vaccination for pediatric health care workers.
    Greer AL; Fisman DN
    Pediatrics; 2011 Sep; 128(3):e591-9. PubMed ID: 21844056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.
    Patel SS; Wagstaff AJ
    Drugs; 1996 Aug; 52(2):254-75. PubMed ID: 8841742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.